Phase 1b clinical trial of ado-trastuzumab emtansine and ribociclib for HER2-positive metastatic breast cancer

Patients with HER2+ metastatic breast cancer are often treated with a multitude of therapies in the metastatic setting, and additional strategies to prolong responses to anti-HER2 therapies are needed. Preclinical evidence suggests synergy between cyclin-dependent kinase 4 and 6 (CDK 4/6) inhibitors...

Descripción completa

Detalles Bibliográficos
Autores principales: Spring, Laura M., Clark, Shealagh L., Li, Tianyu, Goel, Shom, Tayob, Nabihah, Viscosi, Elene, Abraham, Elizabeth, Juric, Dejan, Isakoff, Steven J., Mayer, Erica, Moy, Beverly, Supko, Jeffrey G., Tolaney, Sara M., Bardia, Aditya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8339067/
https://www.ncbi.nlm.nih.gov/pubmed/34349115
http://dx.doi.org/10.1038/s41523-021-00311-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8339067/
https://www.ncbi.nlm.nih.gov/pubmed/34349115
http://dx.doi.org/10.1038/s41523-021-00311-y

Ejemplares similares